Azilsartan Medoxomil
drugOn this page
Also known as AR-14Azilsartan medoxomiloEdarbiTAK 491TAK-491
Summary
Azilsartan Medoxomil (CHEMBL2028661) is an approved small-molecule prodrug (ATC C09CA09); indicated across 3 conditions including cardiovascular disorder and hypertensive disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C09CA09
- Indications: 3 conditions
- Clinical trials: 26
- Chemistry: 568.5 Da · C30H24N4O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2028661 |
| Name | Azilsartan Medoxomil |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 135409642 |
| ChEBI | CHEBI:68845 |
| ATC | C09CA09 |
| Molecular formula | C30H24N4O8 |
| Molecular weight | 568.5 |
| InChIKey | QJFSABGVXDWMIW-UHFFFAOYSA-N |
SMILES: CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C
IUPAC name: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
ChEBI definition: A carboxylic ester obtained by formal condensation of the carboxy group of azilsartan with the hydroxy group of 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one. A prodrug for azilsartan, it is used for treatment of hypertension.
Pharmacological roles (ChEBI): prodrug, angiotensin receptor antagonist, antihypertensive agent.
Also known as: AR-14, Azilsartan medoxomil, Azilsartan medoxomilo, Edarbi, TAK 491, TAK-491, AZILSARTAN MEDOXOMIL
Parent form; salt/anhydrous children: CHEMBL2103795
Patent coverage: 209 distinct patent families (450 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 442 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Type-2 angiotensin II receptor.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| AGTR2 | 8.59 | IC50 | 2.6 | nM | CHEMBL_ACT_26024756 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 3 | MONDO:0004995 | EFO:0000319 |
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| essential hypertension | 3 | MONDO:0001134 | MONDO:0001134 |
Clinical trials
Total trials: 26.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 18 |
| Not specified | 3 |
| PHASE4 | 2 |
| PHASE1 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07547878 | PHASE4 | NOT_YET_RECRUITING | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
| NCT02517866 | PHASE4 | COMPLETED | Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia |
| NCT00591253 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension |
| NCT00591266 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension |
| NCT00591578 | PHASE3 | COMPLETED | Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension |
| NCT00591773 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension |
| NCT00696241 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension |
| NCT00696384 | PHASE3 | COMPLETED | A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension |
| NCT00696436 | PHASE3 | COMPLETED | An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension. |
| NCT00760214 | PHASE3 | COMPLETED | Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension |
| NCT00818883 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension |
| NCT00846365 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension |
| NCT00847626 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension |
| NCT00996281 | PHASE3 | COMPLETED | Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension |
| NCT01033071 | PHASE3 | COMPLETED | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension. |
| NCT01309828 | PHASE3 | COMPLETED | Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease |
| NCT01456169 | PHASE3 | COMPLETED | A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone |
| NCT01496430 | PHASE3 | TERMINATED | Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes |
| NCT02203916 | PHASE3 | COMPLETED | Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension |
| NCT02480764 | PHASE3 | COMPLETED | Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension |
| NCT00362115 | PHASE2 | COMPLETED | Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension |
| NCT01078376 | PHASE1 | TERMINATED | A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults |
| NCT02541669 | PHASE1 | COMPLETED | A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants |
| NCT02756819 | Not specified | COMPLETED | International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan |
| NCT04470817 | Not specified | COMPLETED | A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea |
| NCT05947448 | Not specified | UNKNOWN | Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).